HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens

    loading  Checking for direct PDF access through Ovid


The effective discovery of tumor-specific antigens (TSAs) holds the key for the development of new diagnostic assays and immunotherapeutic approaches against cancer. Here, we discuss our recently developed technologies, HEPA and PARSE, which allow for the systematic identification of TSAs, generating a reservoir of immunologically and clinically relevant targets.

Related Topics

    loading  Loading Related Articles